SG11201903697WA - Liver organoid compositions and methods of making and using same - Google Patents
Liver organoid compositions and methods of making and using sameInfo
- Publication number
- SG11201903697WA SG11201903697WA SG11201903697WA SG11201903697WA SG11201903697WA SG 11201903697W A SG11201903697W A SG 11201903697WA SG 11201903697W A SG11201903697W A SG 11201903697WA SG 11201903697W A SG11201903697W A SG 11201903697WA SG 11201903697W A SG11201903697W A SG 11201903697WA
- Authority
- SG
- Singapore
- Prior art keywords
- cincinnati
- international
- liver
- burnett
- avenue
- Prior art date
Links
- 210000004185 liver Anatomy 0.000 title abstract 5
- 210000002220 organoid Anatomy 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 abstract 2
- 206010072268 Drug-induced liver injury Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract 1
- 206010019663 Hepatic failure Diseases 0.000 abstract 1
- 235000003332 Ilex aquifolium Nutrition 0.000 abstract 1
- 241000209027 Ilex aquifolium Species 0.000 abstract 1
- 206010067125 Liver injury Diseases 0.000 abstract 1
- 206010070863 Toxicity to various agents Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 231100000234 hepatic damage Toxicity 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000008818 liver damage Effects 0.000 abstract 1
- 231100000835 liver failure Toxicity 0.000 abstract 1
- 208000007903 liver failure Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- C12N5/0671—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/067—Hepatocytes
- C12N5/0672—Stem cells; Progenitor cells; Precursor cells; Oval cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Physics & Mathematics (AREA)
- Nutrition Science (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
Abstract
Prearizedorvanoit( . . • • &waded CEMPINO. W O 18/085 6 15 Al FIG. I (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 May 2018 (11.05.2018) WIPO I PCT oimitia °nolo omm Holm onno oimIE (10) International Publication Number WO 2018/085615 Al (51) International Patent Classification: A61K 35/407 (2015.01) C12Q 1/00 (2006.01) C12N 5/00 (2006.01) G01N 33/50 (2006.01) C12N 15/01 (2006.01) (21) International Application Number: PCT/US2017/059845 (22) International Filing Date: 03 November 2017 (03.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/417,371 04 November 2016 (04.11.2016) US 62/517,414 09 June 2017 (09.06.2017) US (71) Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER [US/US]; 3333 Burnett Avenue, Cincinnati, OH 45229 (US). (72) Inventors: TAKEBE, Takanori; c/o 3333 Burnett Avenue, Cincinnati, OH 45229 (US). SHINOZAWA, Tadahiro; c/o 3333 Burnett Avenue, Cincinnati, OH 45229 (US). KIMURA, Masaki; c/o 3333 Burnett Avenue, Cincinnati, OH 45229 (US). KOIKE, Hiroyuki; c/o 3333 Burnett Avenue, Cincinnati, Ohio 45229 (US). (74) Agent: TEPE, Nicole, M. et al.; Frost Brown Todd LLC, 3300 Great American Tower, 301 East Fourth Street, Cincinnati, OH 45202 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). = (54) Title: LIVER ORGANOID COMPOSITIONS AND METHODS OF MAKING AND USING SAME (57) : Disclosed are methods of inducing formation of a liver organoid from precursor cells, such as iPSC cells. The disclosed liver organoids may be used for screening for a serious adverse event (SAE), such as liver failure and/or drug induced liver injury (DILI), and/or drug toxicity. The disclosed liver organoids may also be used to treat an individ- ual having liver damage, or for identifying a preferred therapeutic agent. [Continued on next page] WO 2018/085615 Al MIDEDIMOMMIDEFIE1111111111111111111111111011111111111111111111111111 Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662417371P | 2016-11-04 | 2016-11-04 | |
US201762517414P | 2017-06-09 | 2017-06-09 | |
PCT/US2017/059845 WO2018085615A1 (en) | 2016-11-04 | 2017-11-03 | Liver organoid compositions and methods of making and using same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903697WA true SG11201903697WA (en) | 2019-05-30 |
Family
ID=62076362
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202104575WA SG10202104575WA (en) | 2016-11-04 | 2017-11-03 | Liver organoid compositions and methods of making and using same |
SG11201903697WA SG11201903697WA (en) | 2016-11-04 | 2017-11-03 | Liver organoid compositions and methods of making and using same |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202104575WA SG10202104575WA (en) | 2016-11-04 | 2017-11-03 | Liver organoid compositions and methods of making and using same |
Country Status (11)
Country | Link |
---|---|
US (4) | US20200056157A1 (en) |
EP (3) | EP3534919A4 (en) |
JP (4) | JP7244418B2 (en) |
KR (2) | KR102546194B1 (en) |
CN (3) | CN110381967A (en) |
AU (2) | AU2017353982B2 (en) |
CA (2) | CA3041714A1 (en) |
IL (1) | IL266398A (en) |
NZ (1) | NZ753051A (en) |
SG (2) | SG10202104575WA (en) |
WO (3) | WO2018085615A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
CN113249297A (en) | 2014-05-28 | 2021-08-13 | 儿童医院医疗中心 | Methods and systems for converting precursor cells to stomach tissue via directed differentiation |
EP3207123A1 (en) | 2014-10-17 | 2017-08-23 | Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
US11066650B2 (en) | 2016-05-05 | 2021-07-20 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
US11767515B2 (en) | 2016-12-05 | 2023-09-26 | Children's Hospital Medical Center | Colonic organoids and methods of making and using same |
KR102625361B1 (en) * | 2017-06-09 | 2024-01-18 | 칠드런즈 호스피탈 메디칼 센터 | Liver-like organ compositions and methods of making and using the same |
US20210254012A1 (en) * | 2018-06-09 | 2021-08-19 | Arizona Board Of Regents On Behalf Of Arizona State University | Next generation designer liver organoids and their methods of preparation and use |
CN112823012A (en) * | 2018-09-12 | 2021-05-18 | 儿童医院医学中心 | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
CN112805018A (en) * | 2018-09-27 | 2021-05-14 | 儿童医院医学中心 | Liver support system comprising liver organoids and methods of making and using same |
US20220135942A1 (en) | 2019-03-29 | 2022-05-05 | Nagasaki University | Cultured tissue and method for producing same |
AU2020283043A1 (en) * | 2019-05-31 | 2021-12-23 | Children's Hospital Medical Center | Methods of generating and expanding hematopoietic stem cells |
JP7039045B2 (en) * | 2019-08-26 | 2022-03-22 | 株式会社フェニックスバイオ | Human fatty liver model cells |
JP2023516484A (en) | 2020-03-11 | 2023-04-19 | ビット バイオ リミテッド | Hepatocyte production method |
CN113717850A (en) * | 2020-05-26 | 2021-11-30 | 中国科学院大连化学物理研究所 | Non-alcoholic fatty liver in-vitro model building method based on three-dimensional liver-like chip |
WO2021243526A1 (en) * | 2020-06-01 | 2021-12-09 | 苏州大学附属儿童医院 | Use of specific marker lncrna for neonatal parenteral nutrition-associated liver disease |
AU2021297788A1 (en) * | 2020-06-23 | 2023-02-23 | Children's Hospital Medical Center | Model for insulin resistance |
US20240228972A1 (en) * | 2021-04-28 | 2024-07-11 | National University Corporation Tokyo Medical And Dental University | Method for producing cells |
WO2022236144A1 (en) | 2021-05-06 | 2022-11-10 | Massachusetts Institute Of Technology | Ex vivo tissue explant and graft platform and uses thereof |
CN113430890A (en) * | 2021-07-01 | 2021-09-24 | 驻马店市华中公路设计有限公司 | Permanent composite pavement structure for old asphalt pavement reconstruction and construction device |
CN115125187B (en) * | 2022-06-14 | 2023-04-07 | 创芯国际生物科技(广州)有限公司 | Organ-like in-vitro model of endometritis as well as establishment method and application thereof |
CN115386535B (en) * | 2022-10-26 | 2023-02-03 | 天津外泌体科技有限公司 | Multispectral liver organoid model and drug hepatotoxicity evaluation method based on same |
CN115418386B (en) * | 2022-11-03 | 2023-03-24 | 成都诺医德医学检验实验室有限公司 | Damage healing evaluation method based on skin organoid, model and application |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2415432B (en) | 2001-12-07 | 2006-09-06 | Geron Corp | Islet cells from human embryonic stem cells |
US7510876B2 (en) | 2003-12-23 | 2009-03-31 | Cythera, Inc. | Definitive endoderm |
WO2008002573A2 (en) | 2006-06-27 | 2008-01-03 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions |
EP2089484B1 (en) * | 2006-12-08 | 2011-01-26 | E. I. Du Pont de Nemours and Company | Water-based coating composition |
EP3061808B1 (en) | 2009-02-03 | 2020-08-12 | Koninklijke Nederlandse Akademie van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising said stem cells |
EP2412800A1 (en) * | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
WO2010094694A1 (en) * | 2009-02-23 | 2010-08-26 | F. Hoffmann-La Roche Ag | Assays to predict cardiotoxicity |
MX2011009757A (en) | 2009-03-17 | 2012-02-28 | Axcan Pharma Inc | Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid. |
JP5722885B2 (en) * | 2009-06-18 | 2015-05-27 | セレクティス アーベー | 3D culture system for growth and differentiation of human pluripotent stem (hPS) cells |
CN101696396A (en) * | 2009-10-27 | 2010-04-21 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | Construction method and use of model of hepatitis B virus infection in vivo |
MX2012005927A (en) * | 2009-11-24 | 2012-11-23 | Alder Biopharmaceuticals Inc | Antibodies to il-6 and use thereof. |
EP2550355B1 (en) * | 2010-03-22 | 2016-11-16 | Takara Bio Europe AB | Directed differentiation and maturation of pluripotent cells into hepatocyte like cells by modulation of wnt-signalling pathway |
US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
US20120291096A1 (en) * | 2011-05-12 | 2012-11-15 | Nokia Corporation | Method and apparatus for secure signing and utilization of distributed computations |
AU2013277429B2 (en) | 2012-06-19 | 2016-01-14 | Intercept Pharmaceuticals, Inc. | Preparation, uses and solid forms of obeticholic acid |
US20160237400A1 (en) | 2013-03-15 | 2016-08-18 | The Jackson Laboratory | Isolation of non-embryonic stem cells and uses thereof |
US20160245653A1 (en) | 2013-04-30 | 2016-08-25 | Sangtae Park | Cylindrical resonator gyroscope |
JP6455934B2 (en) | 2013-07-23 | 2019-01-23 | 公立大学法人横浜市立大学 | Method for imparting vasculature to biological tissue |
SG11201607859SA (en) | 2014-03-21 | 2016-10-28 | Tobira Therapeutics Inc | Cenicriviroc for the treatment of fibrosis |
UA121208C2 (en) | 2014-04-11 | 2020-04-27 | Сімабей Терапьютікс, Інк. | Treatment of nafld and nash |
CN113249297A (en) * | 2014-05-28 | 2021-08-13 | 儿童医院医疗中心 | Methods and systems for converting precursor cells to stomach tissue via directed differentiation |
US20170166870A1 (en) * | 2014-06-06 | 2017-06-15 | Vrije Universiteit Brussel | Human hepatic 3d co-culture model and uses thereof |
EP3174874B1 (en) | 2014-07-29 | 2020-09-02 | Shenzhen Hightide Biopharmaceutical Ltd. | Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof |
RU2723559C2 (en) | 2014-09-12 | 2020-06-16 | Тобира Терапьютикс, Инк. | Combined therapy with application of cenicriviroc for fibrosis treatment |
CN107075471A (en) * | 2014-10-08 | 2017-08-18 | 新加坡科技研究局 | Stem cell is divided into the method for hepatocyte lineage |
CN104387451B (en) * | 2014-11-07 | 2020-12-18 | 浙江海洋学院 | Clam enzymolysis oligopeptide with repairing effect on non-alcoholic fatty liver disease cell model and preparation method thereof |
SG11201704291QA (en) * | 2014-11-26 | 2017-06-29 | Accelerated Biosciences Corp | Induced hepatocytes and uses thereof |
US20180021341A1 (en) | 2015-01-09 | 2018-01-25 | Gilead Apollo, Llc | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
US20160256672A1 (en) * | 2015-02-10 | 2016-09-08 | Cedars-Sinai Medical Center | Induced pluripotent stem cell-derived hepatocyte based bioartificial liver device |
CN105985395A (en) | 2015-02-13 | 2016-10-05 | 江苏奥赛康药业股份有限公司 | Obeticholic acid compound, and medicinal composition containing compound |
KR20220070057A (en) | 2015-03-09 | 2022-05-27 | 인테크린 테라퓨틱스, 아이엔씨. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
ES2974281T3 (en) * | 2015-04-07 | 2024-06-26 | Intercept Pharmaceuticals Inc | Pharmaceutical compositions for combination therapy |
US10557124B2 (en) * | 2015-04-22 | 2020-02-11 | The Regents Of The University Of Michigan | Compositions and methods for obtaining stem cell derived lung tissue, and related uses thereof |
PE20180690A1 (en) * | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | OBETICOLIC ACID COMPOSITIONS AND METHODS OF USE |
CN108430220A (en) | 2015-06-30 | 2018-08-21 | 巴斯夫农业公司阿纳姆(荷兰) | A kind of composition and method of pest control |
WO2017048193A1 (en) * | 2015-09-15 | 2017-03-23 | Agency For Science, Technology And Research (A*Star) | Derivation of liver organoids from human pluripotent stem cells |
JP2018532720A (en) | 2015-09-16 | 2018-11-08 | トビラ セラピューティクス, インコーポレイテッド | Senicribiroc combination therapy for the treatment of fibrosis |
US10801068B2 (en) | 2015-10-16 | 2020-10-13 | The Trustees Of Columbia University In The City Of New York | JAG1 expression predicts therapeutic response in NASH |
AU2016348638A1 (en) | 2015-11-06 | 2018-06-07 | Gemphire Therapeutics Inc. | Gemcabene combinations for the treatment of cardiovascular disease |
EP3426766B1 (en) | 2016-03-08 | 2022-12-28 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Method for continuous biosensing |
EP3228306A1 (en) | 2016-04-04 | 2017-10-11 | ratiopharm GmbH | Complex compound comprising obeticholic acid and cyclodextrin and pharmaceutical formulation comprising the complex compound |
US20190255143A1 (en) | 2016-04-18 | 2019-08-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash) |
KR20180129909A (en) | 2016-04-22 | 2018-12-05 | 타이완제이 파마슈티컬스 컴퍼니 리미티드 | Nalmefene, naltrexone or derivatives thereof for use in the treatment of (non) alcoholic fatty liver disease or nonalcoholic fatty liver disease |
KR102625361B1 (en) | 2017-06-09 | 2024-01-18 | 칠드런즈 호스피탈 메디칼 센터 | Liver-like organ compositions and methods of making and using the same |
-
2017
- 2017-11-03 EP EP17867910.6A patent/EP3534919A4/en active Pending
- 2017-11-03 US US16/346,190 patent/US20200056157A1/en active Pending
- 2017-11-03 CA CA3041714A patent/CA3041714A1/en active Pending
- 2017-11-03 JP JP2019522226A patent/JP7244418B2/en active Active
- 2017-11-03 US US16/343,157 patent/US10668108B2/en active Active
- 2017-11-03 EP EP17866743.2A patent/EP3534976A4/en active Pending
- 2017-11-03 SG SG10202104575WA patent/SG10202104575WA/en unknown
- 2017-11-03 US US16/346,188 patent/US20190298775A1/en active Pending
- 2017-11-03 NZ NZ753051A patent/NZ753051A/en unknown
- 2017-11-03 CA CA3041712A patent/CA3041712A1/en active Pending
- 2017-11-03 WO PCT/US2017/059845 patent/WO2018085615A1/en unknown
- 2017-11-03 CN CN201780065705.3A patent/CN110381967A/en active Pending
- 2017-11-03 EP EP17867772.0A patent/EP3534907A4/en active Pending
- 2017-11-03 WO PCT/US2017/059860 patent/WO2018085622A1/en unknown
- 2017-11-03 WO PCT/US2017/059865 patent/WO2018085623A1/en unknown
- 2017-11-03 KR KR1020197014842A patent/KR102546194B1/en active IP Right Grant
- 2017-11-03 KR KR1020237020433A patent/KR20230093079A/en active IP Right Grant
- 2017-11-03 JP JP2019522219A patent/JP7078615B2/en active Active
- 2017-11-03 AU AU2017353982A patent/AU2017353982B2/en active Active
- 2017-11-03 CN CN201780066023.4A patent/CN110382012B/en active Active
- 2017-11-03 SG SG11201903697WA patent/SG11201903697WA/en unknown
- 2017-11-03 CN CN202310951244.7A patent/CN117229994A/en active Pending
-
2019
- 2019-05-01 IL IL266398A patent/IL266398A/en unknown
-
2020
- 2020-04-24 US US16/857,338 patent/US20210008123A1/en active Pending
-
2021
- 2021-08-05 AU AU2021212060A patent/AU2021212060A1/en active Pending
-
2022
- 2022-05-19 JP JP2022082075A patent/JP7545186B2/en active Active
-
2023
- 2023-03-09 JP JP2023036651A patent/JP2023085289A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
SG11201807041PA (en) | Improved preparations of adult liver progenitor cells | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201900486WA (en) | Treatment and prevention of sleep disorders | |
SG11201809051YA (en) | Cell retention device and method | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201805385QA (en) | Bromodomain and extra-terminal protein inhibitor combination therapy | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201900361RA (en) | Methods of treating prostate cancer | |
SG11201805170XA (en) | Cellular glycosaminoglycan compositions and methods of making and using | |
SG11201900123TA (en) | Compositions and methods for treating frontotemporal dementia | |
SG11201805788WA (en) | Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation | |
SG11201906852XA (en) | Treatment of diuretic resistance | |
SG11201900543SA (en) | Gene therapy for the treatment of aldehyde dehydrogenase deficiency |